RxDoctor Payments Data

Megan Spiller

Family · Naples, FLNPI 1104284454

Payments from drug & device makers

$10,494in general payments, 2019–2025

Across 570 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Novo Nordisk$740
  • Astellas Pharma US Inc$690
  • AstraZeneca$595
  • Amgen$592
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$10,31898%
  • Education$1762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,494 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$213,794
Medicare patients
671
Services billed
5,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$94,103
EliquisApixaban45$50,655
XareltoRivaroxaban32$45,552
JardianceEmpagliflozin24$30,343
JanuviaSitagliptin Phosphate18$24,109
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,136
MyrbetriqMirabegron20$18,385
TrulicityDulaglutide13$12,098
QuliptaAtogepant11$11,200
Breo ElliptaFluticasone/Vilanterol14$8,428
SynthroidLevothyroxine Sodium44$3,675
Atorvastatin Calcium313$2,925
Levothyroxine Sodium374$2,695
Omeprazole191$2,676
PaxlovidNirmatrelvir/Ritonavir27$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$740$94,10383 claims
PfizerEliquis, Paxlovid$1,257$53,32972 claims
Johnson & JohnsonXarelto$289$45,55232 claims
GSKTrelegy Ellipta, Breo Ellipta$337$30,56438 claims
Boehringer IngelheimJardiance$210$30,34324 claims
MerckJanuvia$344$24,10918 claims
Astellas Pharma US IncMyrbetriq$690$18,38520 claims
AbbVieQulipta, Synthroid$1,721$14,87555 claims
Lilly USA, LLCTrulicity$435$12,09813 claims
Almatica Pharma LLCSertraline Hcl$112$70877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →